Publicaciones en colaboración con investigadores/as de Iuliu Hațieganu University of Medicine and Pharmacy (53)

2023

  1. Alcohol-related liver disease phenotype impacts survival after an acute variceal bleeding episode

    Liver International, Vol. 43, Núm. 7, pp. 1548-1557

  2. ERN ReCONNET points to consider for treating patients living with autoimmune rheumatic diseases with antiviral therapies and anti-SARS-CoV-2 antibody products

    Clinical and experimental rheumatology, Vol. 41, Núm. 3, pp. 543-553

  3. First-Line Nivolumab Plus Ipilimumab With Chemotherapy Versus Chemotherapy Alone for Metastatic NSCLC in CheckMate 9LA: 3-Year Clinical Update and Outcomes in Patients With Brain Metastases or Select Somatic Mutations

    Journal of Thoracic Oncology, Vol. 18, Núm. 2, pp. 204-222

  4. First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817

    Journal for immunotherapy of cancer, Vol. 11, Núm. 2

  5. First-line nivolumab plus ipilimumab with two cycles of chemotherapy versus chemotherapy alone (four cycles) in metastatic non-small cell lung cancer: CheckMate 9LA 2-year patient-reported outcomes

    European Journal of Cancer, Vol. 183, pp. 174-187

  6. Five-Year Survival Outcomes with Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small-Cell Lung Cancer in CheckMate 227

    Journal of Clinical Oncology, Vol. 41, Núm. 6, pp. 1200-1212

  7. Hepatic encephalopathy is not a contraindication to pre-emptive TIPS in high-risk patients with cirrhosis with variceal bleeding

    Gut, Vol. 72, Núm. 4, pp. 749-758

  8. Liver Transplantation for Porto-sinusoidal Vascular Liver Disorder: Long-term Outcome

    Transplantation, Vol. 107, Núm. 6, pp. 1330-1340

  9. Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis

    Annals of Oncology, Vol. 34, Núm. 2, pp. 173-185

  10. Metabolomics as a tool to predict the risk of decompensation or liver-related death in patients with compensated cirrhosis

    Hepatology (Baltimore, Md.), Vol. 77, Núm. 6, pp. 2052-2062

  11. Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial

    ESMO Open, Vol. 8, Núm. 6

  12. Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817

    Journal of Thoracic Oncology, Vol. 18, Núm. 1, pp. 79-92

  13. Systemic and Intracranial Outcomes With First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC and Baseline Brain Metastases From CheckMate 227 Part 1

    Journal of Thoracic Oncology, Vol. 18, Núm. 8, pp. 1055-1069